Business Context and Reporting Period
Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: The Company develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions (HypoThermosol, CryoStor, BloodStor) for cells, tissues, and organs. It also provides contracted R&D and consulting services for biopreservation optimization.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Total Revenue | $524,892 | $1,505,571 |
| Gross Profit | $224,845 | $649,118 |
| Gross Margin | 43% | 43% |
| Operating Loss | $(286,196) | $(1,078,878) |
| Net Loss | $(436,732) | $(1,512,992) |
| Cash and Cash Equivalents (Sep 30, 2010) | $298 | |
| Total Debt (Related Party Notes) | $8,738,127 (Principal) | |
| Accrued Interest (Related Party) | $1,199,601 | |
| Accumulated Deficit | $(51,724,213) |
Material Changes vs. Prior Period
- Revenue Growth: Product sales increased 18% ($78,366) for the quarter and 38% ($409,572) for the nine-month period compared to 2009, driven by higher sales of BloodStor cord blood stem cell freeze media to existing and new customers.
- Margin Expansion: Gross margin improved significantly to 43% for both the quarter and nine-month period (up from 26% and 29% in 2009, respectively). This reflects the transition from contract manufacturing to internal manufacturing and higher revenue relative to fixed costs.
- Expense Reduction: Operating expenses decreased year-over-year. Sales and marketing expenses dropped 31% (quarter) and 29% (nine-month) due to workforce reductions. R&D expenses decreased 30% for the nine-month period.
- Liquidity Deterioration: Cash and cash equivalents plummeted from $139,151 at year-end 2009 to $298 as of September 30, 2010. Net cash used in operating activities was $972,168 for the nine-month period.
- Debt Restructuring: Long-term related party debt was reclassified as current liabilities. The total principal balance on related party promissory notes increased to $8,738,127.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states that the accumulated deficit of approximately $52 million and inability to generate sufficient operating income raise substantial doubt about the Company's ability to continue as a going concern.
- Liquidity Strategy: The Company relies on a Secured Convertible Multi-Draw Term Loan Facility from related parties (Thomas Girschweiler and Walter Villiger). As of September 30, 2010, $261,873 remained available to draw. Management expects to negotiate an extension and increase of these facilities by November 30, 2010.
- Capital Needs: The Company expects to require additional capital to reach sustainable positive cash flow. There is no assurance that additional financing will be available or that terms will not be dilutive.
- Subsequent Event: In October 2010, the Company received an additional $250,000 from the related party investors.
- Risks: Risks include potential termination of the credit facilities, significant revenue reductions, increased capital expenditures, and adverse outcomes from current litigation.
Investor Verification Checklist
- Cash Runway: Verify the status of negotiations to extend the related party credit facilities, as cash on hand is effectively zero ($298).
- Debt Maturity: Confirm the repayment terms and interest accrual on the $8.7 million related party debt, which is currently classified as current.
- Revenue Sustainability: Assess the durability of the 38% revenue growth and whether it is sufficient to offset the high interest expense ($432,628 for nine months).
- Going Concern Status: Review the latest filings for any updates on the "substantial doubt" regarding the Company's ability to continue operations.
- Dilution Risk: Monitor for any new equity financing, which may be required if debt facilities are restricted, potentially diluting existing shareholders.